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Granulocyte colony-stimulation factor (G-CSF) is a cytokine that
selectively promotes growth and maturation of neutrophil progen-
itor cells by interacting with a specific cell surface receptor
(G-CSFR) (Dmetri and Griffin, 1991; Avalos, 1996). Recombinant
human G-CSF (r-metHuG-CSF, Filgrastim) has been effective in
ameliorating neutropenia and reducing the rate of infection in
chemotherapy-treated cancer patients, as well as in patients with
severe chronic neutropenia (Lieschke and Burgess, 1992;
Naparstek, 1996). It can also mobilize progenitor cells from the
bone marrow into peripheral blood that can be used for hematopoi-
etic reconstitution (Molineux et al, 1990; Bensinger et al, 1995;
Schmitz et al, 1995). In addition to its role in the regulation of
granulopoiesis, G-CSF enhances functions of mature neutrophils
such as phagocytosis (Roilides et al, 1991), respiratory burst
(Sullivan et al, 1993) and microbicidal activity (Vechiarelli et al,
1995). G-CSF has been shown to facilitate the clinical recovery of
the nonneutropenic host in several animal models of infection
(Dale et al, 1995) and in clinical trials of non-neutropenic patients
with pneumonia (Welte et al, 1996).
G-CSF may also modulate the cytokine response to inflamma-
tory stimuli. In mice, G-CSF pre-treatment attenuated the release
of tumour necrosis factor alpha (TNF-a) and reduced the mortality
induced by endotoxin administration (Gorgen et al, 1992). In one
study, healthy volunteers were treated with G-CSF and the blood
was collected at several time points to measure cytokine release in
response to different stimuli such as phorbol esters and phyto-
haemagglutinin (PHA). G-CSF administration caused a significant
reduction in the release of TNF-a by stimulated whole blood
(Hartung et al, 1995).
Recent observations suggest that G-CSF may also regulate the
function of T lymphocytes. In a murine model of T-cell-mediated
lethal shock induced by superantigens, G-CSF pre-treatment led to
a reduction in mortality accompanied by diminished interleukin
(IL)-2 production in vivo (Aoki et al, 1995). In a murine model of
graft-versus-host disease, G-CSF administration induced an
improvement in survival that was associated with a significant
decrease in the production of IL-2 and interferon gamma (IFN-g)
by T lymphocytes incubated with alloantigens or mitogens (Pan
et al, 1995).
To assess whether G-CSF has an effect on the function of
T lymphocytes from humans, we have studied ex vivo the prolifer-
ative response to polyclonal T lymphocyte mitogens of peripheral
blood mononuclear cells (PBMC) from breast cancer patients
treated with G-CSF for peripheral blood progenitor cell (PBPC)
mobilization. In these PBMC, we have also studied the cytokine
production after mitogenic activation and the distribution of
T lymphocyte subsets. Our data showed that G-CSF treatment
induces an increase in peripheral blood lymphocyte counts and a
significant reduction in the proliferative response of PBMC to
mitogenic stimulation which reverted 14 days after the end of
treatment with G-CSF. These results were not associated with
significant changes in the pattern of cytokine production.
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Summary Granulocyte colony-stimulation factor (G-CSF) is a cytokine that selectively promotes growth and maturation of neutrophils and
may modulate the cytokine response to inflammatory stimuli. The purpose of this study was to examine the effect of G-CSF on ex vivo
peripheral blood mononuclear cell (PBMC) functions. Ten patients with breast cancer were included in a clinical trial in which r-metHuG-CSF
was administrered daily for 5 days to mobilize peripheral blood stem cells. Ten healthy women were also included as controls. Our data show
that G-CSF treatment induces an increase in peripheral blood leucocyte, neutrophil, lymphocyte and monocyte counts. We have found a
modulation in the percentages of CD19+, CD45+CD14+, CD4+CD45RA+ and CD4+CD45RO+ cells in PBMC fractions during G-CSF
treatment. We have also found a significant reduction in the proliferative response of PBMC to mitogenic stimulation that reverted 14 days
after the fifth and the last dose of G-CSF. Furthermore, it was not associated with significant changes in the pattern of cytokine production.
The mechanism of this immunoregulatory effect is probably indirect since G-CSF receptor has not been found in T lymphocytes. This
mechanism and its potential clinical applications remain to be elucidated.
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Patients features
Ten patients (mean age 42.5 years, range 29–61) were included in
this study after giving informed consent, all had breast cancer and
were enrolled in a protocol for PBPC transplantation. Patients
were either in high-risk stages II and III breast cancer, or stage IV
of complete clinical remission. All patients had received, prior to
mobilization, six cycles of FEC adjuvant cancer chemotherapy
(5-fluorouracil, 600 mg m–2, 4-epirubicin, 75 mg m–2 and
cyclophosphamide 600 mg m–2) which was repeated every 21
days. None of the patients had other significant intercurrent
disease (AIDS, congenital immunodeficiency, lymphoma,
leukaemia or myelodysplastic syndrome, LES, rheumatoid
arthirits, fever or psychiatric disease). No previous treatment with
G-CSF, GM-CSF, radiotherapy, systemic corticoids, IFN or IL-2
were administered. Ten age-matched healthy women were used as
controls.
Study design
PBPC were mobilized from the bone marrow to the peripheral
blood with G-CSF at a dose of 10 mg kg–1 day–1 (Filgrastim,
Neupogen®, AMGEN, Thousand Oaks, CA, USA and Hoffman-
LaRoche, Basel, Switzerland) for 5 consecutive days (Figure 1).
Mobilization was started 5 or 6 weeks after the administration of
the last FEC chemotherapy course (five patients at the fifth week
and five patients at the sixth week). The pheresis procedures were
started on fifth day of mobilization and were continued until a
minimum of 2.5 million of CD34+ cells kg–1 were collected.
Blood samples for this study were collected before the first dose
of G-CSF, 24 h after the first dose, 24 h after the fourth dose and
14 days after the fifth and the last dose of treatment (Figure 1). For
each patients, the same healthy volunteers were used throughout
the study. Blood from healthy donors was withdrawn and simulta-
neously processed with that of the patients. White blood cell
(WBC) counts were assessed at each point of blood collection
using a Coulter STKS (Coulter, Krefeld, Germany).
Cell separation
PBMC were obtained by centrifugation in a Ficoll-Hypaque
(Lymphoprep Nyegaard and Co., Oslo, Norway) density gradient
as previously described (Boyum, 1968). After counting, cells were
resuspended in RPMI-1640 (Whitaker Bioproducts, Walkersville,
USA) supplemented with 10% heat-inactivated fetal bovine serum
(Biochrom KG, Berlin, Germany), L-glutamine (2 mM; Biochrom
KG), HEPES (25 mM; Biochrom KG) and 1% penicillin–strepto-
mycin (Difco Lab, Detroit, MI, USA). This will be referred to as a
complete medium. Cell viability, as checked by trypan blue exclu-
sion, was always greater than 95%.
Staining and FACS analysis
For immunofluorescence, PBMC were incubated with combina-
tions of fluorescein (FITC, green), phycoerythrin (PE, orange) and
peridinin chlorophyll protein conjugate (PerCP, red)-labelled
monoclonal antibodies (mAbs). These were used in three-colour
combinations to define the PBMC preparations and activated cells
(FITC/PE/PerCP). The mAbs used in this study were anti-CD19
(B-cells), anti-CD56 (N-CAM, defines NK cells as CD3–CD56+
and also non-MHC restricted T lymphocytes CD3+CD56+),
anti-CD3 (T lymphocytes), anti-CD4 (MHC class II restricted
T lymphocytes), anti-CD8 (MHC class I restricted T lympho-
cytes), anti-HLA-DR (MHC class II molecules), anti-CD25 (p55,
IL-2Ra), anti-CD57 (HNK-1, MHC non-restricted cytotoxicity
after activation), anti-CD45RO (primed T-cells), anti-CD45RA
(unprimed T-cells), anti-IgG, anti-IgM, anti-IgD and anti-CD14
(monocytes). Control studies with unstained cells and cells
incubated with isotype-matched irrelevant FITC-, PE- and PerCP-
labelled mAbs were performed for each experiment. All mAbs
were obtained from Becton Dickinson (Mountain View, CA,
USA). Tri-colour immunofluorescent analysis was performed with
a FACScan flow cytometer and Lysis II software (Becton
Dickinson). For lymphocyte and monocyte population study, a
biparametric gate in the FSC-SSC dot plot was drawn around the
population as defined by an antigen expression of CD45+CD14–
or CD45+CD14+ respectively.
Proliferation studies
PBMCs (50 000 cells well–1) were cultured in complete medium
on 96-well, flat-bottomed microtitre plates (Nunc Corporation,
Roskilde, Denmark) in the presence or absence of phytohaemag-
glutinin (PHA, 10 mg ml–1; Difco Lab, MI, USA), concanavalin A
(Con A, 2 mg ml–1; Sigma Chemical Co., MI, USA) and immobi-
lized anti-CD3 (5 mg ml–1, Ortho-mune; Orthodiagnostic System).
This reagent was tested in dose–response titrations before use.
Cultures were incubated at 37°C in a 95% humid atmosphere
containing 5% carbon dioxide for 3 and 5 days. DNA synthesis
was measured during the last 18 h of the culture period by
incorporation of [3H]thymidine (1 mCi; Radiochemical Centre,
Amersham, UK) and was expressed in count per minute (cpm).
Cultures were performed in triplicate. The standard deviation
between replicates was < 10%.
Measurement of cytokine productions
To measure production of cytokine, 2.5 ´ 106 PBMCs from
patients and healthy controls were cultured in 1 ml of complete
medium in the presence or absence of PHA (10 mg ml–1; Difco
Lab, MI, USA). Cell cultures were maintained for 72 h in an
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Figure 1 Summary of the mobilization treatment schemeincubator at 37°C in a 95% humid atmosphere containing 5%
carbon dioxide. The culture supernatants were then harvested,
sterilized by filtration through an 0.22 mm filter (Millipore
Company, Bedford, CA, USA) separated into aliquots and imme-
diately stored at –70°C until further use. Cytokine levels in cell
culture supernatants were determined in duplicate using the
commercially available specific IL-1, IL-6, TNF-a and IFN-g,
enzyme-linked immunosorbent assay (ELISA) kits (Quantikine,
RandD Systems, MN, USA), IL-2 ELISA kit (T Cell Diagnostics;
Cambridge, MA, USA) and the IL-10 ELISA kit (Bender
MedSystems, Vienna, Austria). Each data point is the average of
two determinations, neither of which varied within 10% of the
final average. Results are expressed in pg ml–1. The lower detec-
tion limit of the IL-1, IL-2, IL-6, IL-10, TNF-a and IFN-g test kits
was 0.3, 15, 0.7, 3.75, 4.4 and 5 pg ml–1 respectively.
Statistical analysis
Differences in the haematological WBC determination, immune
phenotype, proliferation and cytokine release during G-CSF treat-
ment were assessed with analysis of variance (ANOVA) for
repeated measurements. Comparison of the measures for the same
parameters between patients and healthy controls were tested with
Mann–Whitney  U-test. Correlation between parameters were
analysed with Pearson’s test. P-values were considered significant
when less than 0.05. Values reported in the text, tables and figure
are means ± standard deviation (s.d.).
RESULTS
G-CSF treatment induces an increase in PBMC cells
and a transitory switch in certain immune cell subsets
Blood was collected before the first dose of G-CSF (10 mg kg–1
dsc–1), 24 h after the first dose, 24 h after the fourth dose and 14
days after the fifth and the last dose of G-CSF treatment (Figure 1).
First, the effects of G-CSF treatment in the absolute count of
leucocytes in the peripheral blood of patients was studied. No
significant differences were found in haematological WBC deter-
minations between healthy controls and patients before G-CSF
treatment. However, as can be seen in Table 1, a significant
increase in the absolute count of total leucocytes, neutrophils,
lymphocytes and monocytes was observed in peripheral blood
from patients at 24 h after the first dose of G-CSF. This increase
was maintained 24 h after the fourth dose of G-CSF treatment with
respect to pre-treatment conditions (P < 0.05). The monocyte
count increase, 24 h after the fourth dose of G-CSF, was signifi-
cantly higher than that found after the first dose (P < 0.05).
However, no significant differences were found in basophile and
eosinophile absolute counts at the different time points of the
study. Fourteen days after the fifth and the last dose of G-CSF,
these changes in cellular counts were no longer significantly
different from the values before G-CSF treatment.
Since an increase in lymphocyte counts during G-CSF adminis-
tration was found, we proceeded to study the distribution of the
T lymphocyte subsets in PBMC from these patients (Table 2).
G-CSF treatment did not induce significant variations in the
percentage of CD3+, CD4+ and CD8+ cells in PBMC from
patients. The expression of activation antigen markers HLADR
and CD25 (IL-2Ra) by CD3+ cells were not significantly modi-
fied by the G-CSF treatment. Twenty-four hours after the fourth
dose of G-CSF there was a significant reduction in the percentage
of CD4+CD45RA+ naive T-cells associated with a concomitant
increase of the CD4+CD45RO+ memory T-cells compared with
pre-treatment values (P < 0.05). Fourteen days after the fifth and
the last dose of G-CSF treatment, this switch in the expression of
the RA/RO CD45 isoforms by CD4+ T-cells was reverted. G-CSF
treatment did not induce significant modifications in either the
percentages of CD56+, CD56+CD3– (Table 2) or of CD3+CD56+,
CD3+CD57+, CD57+CD8+CD8+CD3–, CD8+CD3+ (data not
shown). In agreement with haematological WBC determinations,
previously described, the percentage of CD45+CD14+ monocytes
observed 24 h after the fourth dose of G-CSF treatment was
significantly higher than that found before treatment (P < 0.05).
We did not find significant differences in the expression of the
different lymphocyte and monocyte subset markers between
PBMC from patients before G-CSF treatment and healthy
volunteers.
G-CSF treatment is associated with a reduced
proliferation of PBMC in response to T-cell activation
signals
The effects of G-CSF treatment on the proliferative response of
PBMC to different T-cell polyclonal mitogens was analysed at
5 days of culture (Figure 2). Before G-CSF treatment, PBMC
from patients and healthy volunteers showed similar proliferative
response to PHA (patients: 120 196 ± 24 627 cpm; controls:
160 437  ± 32 805 cpm), Con A (patients: 97 986 ± 21 069 cpm;
controls: 131 106 ± 27 002 cpm) and anti-CD3 (patients:
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Table 1 Cell recovery (103 mm–3) before, throughout and after G-CSF treatment
Pre-treatment After the After the Fourteen days after
first dose fourth dose the last dose
Leucocytes 4747 ± 1949 30327 ± 10499a 35298 ± 12099a 7080 ± 3318
Neutrophils 3084 ± 1454 27706 ± 10183a 29845 ± 11017a 5373 ± 4000
Lymphocytes 990 ± 538 1439 ± 241a 1944 ± 452a 3318 ± 1000
Monocytes 375 ± 216 1023 ± 417a 2068 ± 891a,b 419 ± 348
Basophiles 26 ± 13 97 ± 60 223 ± 166 43 ± 43
Eosinophiles 106 ± 99 157 ± 131 1114 ± 1000 175 ± 70
WBC counts were assessed at each point of blood collection using a Coulter STKS (Coulter, Krefeld, Germany). Data are expressed in
number of cells ´ 103 mm–3 and are represented as mean ± S.D. aP < 0.05 versus before G-CSF treatment. bP < 0.05 versus 24 hours
after the first dose of G-CSF.144 070 ± 28 328 cpm; controls: 147 097 ± 34 445 cpm). Twenty-
four hours after the first dose of G-CSF, we observed a non-
significant reduction in the PBMC proliferation induced by these
mitogenic signals. However, 24 h after the fourth dose of G-CSF
this proliferation was further reduced and became significantly
lower than the values before G-CSF treatment (P < 0.05). This
proliferation reduction had partially disappeared 14 days after the
fifth and the last dose of G-CSF. There were no significant differ-
ences between the proliferative response of PBMC to mitogenic
stimulation before G-CSF treatment and 14 days after the fifth and
the last G-CSF dose. Similar results were observed after 3 days of
culture (data not shown). G-CSF treatment is also associated with
a reduced proliferation of purified non-adherent cells in response
to T-cell activation signals (manuscript in preparation).
PBMC from patients or controls cultured in absence of mito-
genic stimulation did not show any significant proliferation at
different times of the study (data not shown). There were no
significant differences in the percentages of viable cells found in
the PBMC cultures from patients and controls at each time point of
the study (data not shown).
The question arises whether this observed decrease in the prolif-
erative response of PBMC from G-CSF-treated patients was
232 E Reyes et al
British Journal of Cancer (1999) 80(1/2), 229–235 © Cancer Research Campaign 1999
Table 2 CD45+CD14– and CD45+CD14+ populations in PBMC cell fractions from patients and healthy volunteers
Antigens G-CSF-treated patients Healthy
Pre-treatment After the After the Fourteen days
volunteers
first dose fourth dose after the last dose
Lymphocytes
CD45+CD14–
CD3+ 57.9 ± 10.9 55.9 ± 19.0 53.9 ± 19.6 57.9 ± 10.2 69.5 ± 8.0
CD4+ 35.3 ± 10.5 35.6 ± 16.9 29.6 ± 13.3 33.6 ± 9.7 42.6 ± 10.1
CD8+ 40.3 ± 8.9 36.8 ± 9.2 36.3 ± 13.0 40.5 ± 8.5 37.8 ± 8.4
CD3+HLADR+ 9.1 ± 7.4c 9.3 ± 6.0 8.8 ± 6.1 8.9 ± 9.9 4.2 ± 3.3
CD3+CD25+ 8.6 ± 7.6 13.3 ± 11.3 9.2 ± 9.2 8.8 ± 4.2 8.4 ± 9.2
(IL-2Ra)
CD4+CD45RA+ 21.4 ± 8.7 17.2 ± 13.7 12.1 ± 5.4a 14.5 ± 7.1 25.6 ± 14.0
CD4+CD45RO+ 14.1 ± 8.7 14.2 ± 8.7 24.2 ± 11.9a 15.7 ± 5.1 15.3 ± 5.1
CD8+CD45RA+ 28.1 ± 6.2 28.2 ± 8.9 23.4 ± 5.4 29.7 ± 9.6 27.4 ± 6.6
CD8+CD45RO+ 14.3 ± 7.8 11.7 ± 4.3 13.0 ± 13.5 12.5 ± 4.8 12.3 ± 5.6
CD19+ 11.2 ± 2.9 10.5 ± 3.7 14.4 ± 4.9b 10.4 ± 3.9 8.0 ± 1.8
CD56+ 37.1 ± 12.3 38.7 ± 18.2 36.2 ± 18.1 36.7 ± 11.5 29.0 ± 12.3
CD56+CD3– 29.8 ± 10.3 33.6 ± 18.3 30.4 ± 18.6 31.7 ± 10.3 22.4 ± 9.3
Monocytes
CD45+CD14+ 29.5 ± 11.5 34.6 ± 10.0 43.2 ± 13.0a 25.0 ± 7.8 21.9 ± 7.5
Blood was collected before the first dose of G-CSF, 24 h after the first dose, 24 h after the fourth dose and 14 days after the fifth and the last
dose of treatment. For immunofluorescence, PBMC were incubated with combinations of fluorescein (FITC, green), phycoerythrin (PE, orange)
and peridinin chlorophyll protein conjugate (PerCP, red)-labelled mAbs. These were used in three-colour combinations to define the PBMC
preparations and activated cells in each tube. Results are expressed in percentage of positive cells and are represented as the mean ± s.d.
aP < 0.05 versus before the G-CSF treatment and 14 days after the fifth and the last dose of G-CSF treatment. bP < 0.05 versus 24 h of G-CSF
treatment and 14 days after the fifth and the last dose of G-CSF treatment. cP < 0.05 versus healthy controls.
Table 3 Cytokine production before, throughout and after G-CSF subcutaneous injection at 72 h of culture
Cytokine G-CSF-treated patients Healthy
release volunteers
Pre-treatment After the After the Fourteen days after
first dose fourth dose the last dose
IL-1 631 ± 306 491 ± 406 378 ± 325 590 ± 599 633 ± 16
IL-2 29 ± 31 20 ± 15 41 ± 36 20 ± 18 441 ± 283
IL-6 1775 ± 339 1558 ± 116 1469 ± 85 1822 ± 328 1459 ± 11
IL-10 176 ± 163 476 ± 609 65 ± 63 363 ± 378 335 ± 49
TNF-a 660 ± 567 392 ± 184 538 ± 459 397 ± 310 459 ± 129
IFN-g 435 ± 588 701 ± 1134 1942 ± 3079 1120 ± 1390 3833 ± 2823
To measure production of cytokine, 2.5 ´ 106 PBMCs from patients and healthy volunteers were cultured in 1 ml of complete
medium in the presence or absence of PHA (10 mg ml–1). Cell cultures were maintained for 72 h in an incubator at 37°C in a 95%
humid atmosphere containing 5% carbon dioxide. Results are expressed in pg ml–1 and represented as the mean ± s.d.explained by an increase in the number of CD19+ and
CD45+CD14+ cells. We analysed the relationship between these
phenotypical characteristics and the proliferative response to PHA
at 5 days of culture. There were no significant correlations
between proliferative response of PBMC to PHA at the different
time points of the study and the corresponding percentages of
CD3+, CD19+ and CD45+CD14+ cells (data not shown).
Cytokine production
We have also analysed the cytokine production by PHA-stimulated
PBMC (Table 3). No significant differences were observed in the
production of IL-1, IL-2, IL-6, IL-10, TNF-a or IFN-g by PHA-
stimulated PBMC from the patients before G-CSF treatment and
healthy controls. During G-CSF treatment there were no signifi-
cant changes in the production of these cytokines by PHA-stimu-
lated PBMC from patients.
We have not found significant differences between the pheno-
typical and functional parameters analysed in PBMC from patients
who received G-CSF treatment 5 weeks or 6 weeks after the
administration of the last FEC chemotherapy course (data not
shown).
DISCUSSION
G-CSF stimulates the proliferation and maturation of myeloid
progenitor cells to neutrophilic granulocytes (Dmetri and Griffin,
1991; Welte et al, 1996). As expected, G-CSF administered to our
patients was associated with a large increase on absolute number
of leucocytes and neutrophils from peripheral blood (Sica et al,
1996). As previously described, we observed a rise in monocyte
counts induced by G-CSF (Hartung et al, 1995; Pollmacher et al,
1996; Sica et al, 1996). Although it has been reported that lympho-
cyte production in humans and mice is not affected by G-CSF
(Bronchud et al, 1987; Pollmacher et al, 1996), we have observed
that G-CSF induces a significant increase in peripheral blood
lymphocyte counts. Different G-CSF effects might be involved in
the induction of this lymphocytosis. A potential effect of G-CSF in
the proliferation and maturation of mononuclear leucocyte precur-
sors may be taken into an account. G-CSF treatment may also
modify the tissular distribution of mature lymphocytes as well as
their peripheral blood traffic.
As far as we know, this is the first reported observation that
G-CSF treatment modulates the proliferative response of PBMC
to T-cell mitogens in humans. The proliferation was reduced after
the first injection of G-CSF, continued to decline throughout the
duration of G-CSF administration and reverted after the end of
G-CSF treatment. The mechanism of this immunoregulatory effect
is probably indirect since G-CSFR have not been found on
T lymphocytes (Shimoda et al, 1992). Proliferation of T-cells in
response to antigens and polyclonal mitogens involves the secre-
tion of IL-2 and the binding to its receptor on T lymphocytes
(Green and Thompson, 1994; Szamel et al, 1995). It has been
observed that G-CSF-treated mice show a reduced production of
IL-2 in vivo in response to bacterial superantigens and in mixed
lymphocyte reactions in vitro (Aoki et al, 1995). However, in our
study, we did not observe either a reduced production of IL-2 or
down-regulation in the expression of IL-2Ra (CD25) on PBMC
following G-CSF administration. The analysis of our data shows a
reduction in the PHA-induced IL-2 production by PBMC from
patients before G-CSF treatment, but without statistical signifi-
cance compared to that of healthy volunteers. Since the prolifera-
tive response of patients’ PBMC to PHA is normal, the reduced
IL-2 production observed in these cellular preparations does not
appear to have functional significance. Furthermore, the absence
of significant modifications in the IL-2 production by PBMC from
patients after G-CSF treatment indicate that the defective prolifer-
ative response of these cellular preparations cannot be explained
by a impaired production of this cytokine.
Both, in humans and mice, G-CSF administration induces
important changes in the release of cytokines from monocytes.
In a murine model of endotoxaemia, G-CSF administration was
associated with reduced TNF-a serum levels (Gorgen et al, 1992;
Kuhns et al, 1995). G-CSF administration to healthy humans
caused a reduction in the production of TNF-a and IFN-g by
G-CSF and T-cell proliferation 233
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Figure 2 Proliferative response of PBMC from patients at 5 days of in vitro
culture in presence of PHA (10 mg ml–1), Con A (2 mg ml–1) and anti-CD3
(5 mg ml–1. Values are expressed in cpm and represented as the mean ± ES.
aP < 0.05 versus before G-CSF treatmentlipopolysaccharide-stimulated blood (Hartung et al, 1995).
Simultaneously, there was an increase of IL-1 receptor antagonist
IL-1ra and soluble TNF receptor (sTNFR) levels induced by
lipopolysaccharide 14. Since it is known that several cytokines
such as IL-1, IL-6 and IFN-g play a relevant role in the prolifera-
tion of T lymphocytes, we examined whether changes in the
production of these mediators could account for the reduced T-cell
proliferation. However, we did not observe a decreased production
of any of these cytokines by PBMC from G-CSF-treated patients
in response to a potent stimulus such as PHA.
Some cytokines, such as IL-10, may attenuate T-cell prolifera-
tion by interfering with antigen presentation by macrophages
(Nakagomi et al, 1995). We investigated whether up-regulation
of IL-10 secretion may explain the observed reduction of T-cell
proliferation, but we could not observe any significant production
by PBMC from patients during G-CSF treatment.
The activation and growth requirements of CD4+ and CD8+
T lymphocyte subsets, as well as those of their different matura-
tion stages, defined by the expression of RA and RO isoforms of
the CD45 antigen, are different (Parnes, 1982; De Jong et al,
1991). Variations in the distributions of these lymphocyte subsets
provoke changes in the proliferation of PBMC (Roman et al,
1996). In our study, the percentage of CD4+ and CD8+ T lympho-
cytes did not change during G-CSF treatment. However, the
observed expansion of CD4+CD45RO+ T-cells and concomitant
decrease of the naive CD4+CD45RA+ populations may be
involved in the functional effects of G-CSF on PBMC.
It remains to be elucidated whether G-CSF may induce lympho-
cyte anergy–apoptosis. It is known that oxidative stress favours
both apoptosis and anergy of T lymphocytes (Buttke and
Sandstrom, 1994) and that G-CSF enhances superoxide produc-
tion by mature neutrophils (Tsuji et al, 1994). The effects of
the superoxide production induced by G-CSF treatment on the
T lymphocyte functions remain to be defined.
The functional effects of the antigen presentation by accessory
cells to T lymphocytes are dependent on different signals (Tsuji
et al, 1994; Terashima et al, 1995). These signals regulate the
progression of the antigen-primed T lymphocytes to activation–
proliferation or anergy – apoptosis pathways. The interaction of
different molecules on the surface of accessory cells such as
CD80–CD86 with the corresponding counterparts such as CD28
and CTLA-4 on the T lymphocyte surface, regulates the progres-
sion of antigen-primed cells to activation or anergy–apoptosis. A
potential effect of G-CSF treatment on the expression of these
molecules may be to trigger the progression of the T lymphocytes
in an anergy–apoptosis pathway.
It may be possible to consider that the immunological modifica-
tions observed in G-CSF-treated patients might be part of a
recovery phase following chemotherapy instead of due to this
cytokine treatment. However, several findings indicate that the
immunological variations were due to G-CSF treatment (Sica et al,
1996). Before G-CSF treatment, the phenotypical and functional
analysis of PBMC from the patients did not show substantial
differences with respect to those found in healthy controls. In all
the cases analysed, the modifications were observed after the first,
and mainly the fourth, dose of G-CSF. Furthermore, there were no
significant differences between the immunological parameters
studied on PBMC from the patients analysed 5 or 6 weeks after the
last FEC course.
As with the patients in our study, it has become routine clinical
practice to administer G-CSF to mobilize from the bone marrow
into the PBPC being used for autologous bone marrow transplant.
G-CSF has also been used for the mobilization of PBPC in normal
volunteers and subsequent transplantation to patients (Welte et al,
1996). It is intriguing that allogeneic PBPC transplantation is not
associated with an incidence of graft-versus-host disease higher
than in conventional bone marrow transplantation despite the fact
that PBPC contains tenfold more T lymphocyte than bone marrow
infusions (Pan et al, 1995). Our finding, which indicates a
reduction of T-cell proliferation following G-CSF injection, may
explain this observation. The reported improvement of inflamma-
tory bowel disease by G-CSF (Roe et al, 1992) may also be related
to this effect on T lymphocyte activation.
In conclusion, we have shown that G-CSF causes a reversible
decrease in T lymphocyte activation in humans. The mechanism of
this effect and its potential clinical applications remains to be
elucidated.
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